Special Issue

Vaccines as Allies in the Malaria Eradication Effort

Message from the Guest Editor

Malaria remains a major global health threat. Increasing resistance of Plasmodium against anti-malarial drugs and decreasing effectiveness of insecticides are still the greatest challenges facing the eradication campaign. The development of an efficacious malaria vaccine has been a focal point of malaria research. Current efforts to generate an efficacious vaccine range from testing different vaccine platforms to including various vaccine antigens that are targeted as they are crucial for the survival and/or functionality of the parasite. Also, while pre-erythrocytic and blood-stage based vaccines intended to prevent or alleviate disease, promising transmission blocking vaccines are being developed, which are considered altruistic vaccines since they contribute to malaria eradication at the population level. but do not directly benefit the vaccinee. This Special Issue will provide an overview over the strategies targeting different life stages of Plasmodium, application of different vaccine platforms and regimens to increase vaccine efficacy, summarizing the state-ofthe-art in the field of malaria vaccine research.

Guest Editor

Dr. Elke S. Bergmann-Leitner

Department of Primary Appointment, School of Medicine, Silver Spring, MD 20910, USA

Deadline for manuscript submissions

closed (31 March 2019)



Diseases

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed



mdpi.com/si/14382

Diseases Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 diseases@mdpi.com

mdpi.com/journal/diseases





Diseases

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed





About the Journal

Message from the Editorial Board

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, Diseases is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biochimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

Prof. Dr. Omar Cauli

Frailty and Cognitive Impairment—FROG Research Group, University of Valencia, 46010 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.